Get the Stockscreener App
0.7228
0.32%
0.0023
After Hours:
.76
0.0372
+5.15%
Prokidney Corp stock is traded at $0.7228, with a volume of 331.56K.
It is up +0.32% in the last 24 hours and down -18.38% over the past month.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
See More
Previous Close:
$0.7205
Open:
$0.7135
24h Volume:
331.56K
Relative Volume:
0.42
Market Cap:
$93.63M
Revenue:
-
Net Income/Loss:
$-35.47M
P/E Ratio:
-1.2681
EPS:
-0.57
Net Cash Flow:
$-124.27M
1W Performance:
+1.72%
1M Performance:
-18.38%
6M Performance:
-63.86%
1Y Performance:
-82.79%
1-Day Range:
$0.6824
$0.7333
1-Week Range:
$0.6824
$0.7403
52-Week Range:
$0.4603
$4.2575
Prokidney Corp Stock (PROK) Company Profile
Name
Prokidney Corp
Sector
Industry
Phone
336-999-7028
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
0.7228 | 95.46M | 0 | -35.47M | -124.27M | -0.57 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-24 | Initiated | JP Morgan | Neutral |
| Sep-10-24 | Initiated | Guggenheim | Buy |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-23 | Initiated | BTIG Research | Buy |
| Dec-21-22 | Initiated | Jefferies | Buy |
| Nov-10-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-18-22 | Initiated | UBS | Buy |
| Oct-14-22 | Initiated | Citigroup | Buy |
| Sep-23-22 | Initiated | BofA Securities | Buy |
| Sep-02-22 | Initiated | Evercore ISI | Outperform |
View All
Prokidney Corp Stock (PROK) Latest News
Northern Trust Corp Has $1.51 Million Position in ProKidney Corp. (NASDAQ:PROK) - Defense World
ProKidney quarterly loss grows as it nears two key milestones - Winston-Salem Journal
ProKidney Up 26%, Insiders Still In The Red By US$35m - simplywall.st
Wells Fargo & Company MN Purchases 18,431 Shares of ProKidney Corp. (NASDAQ:PROK) - Defense World
ProKidney (PROK) Eyes Key Developments and Strong Financial Outl - GuruFocus
ProKidney Corp. Reports Increased Losses Amid Ongoing R&D - TipRanks
ProKidney (PROK) Eyes Key Developments and Strong Financial Outlook | PROK Stock News - GuruFocus
PROKIDNEY CORP. SEC 10-Q Report - TradingView
ProKidney Reports First Quarter 2025 Financial Results and Business Highlights - The Manila Times
ProKidney Corp. (NASDAQ:PROK) Shares Bought by Barclays PLC - Defense World
Mariner LLC Has $64,000 Stake in ProKidney Corp. (NASDAQ:PROK) - The AM Reporter
Mariner LLC Sells 15,937 Shares of ProKidney Corp. (NASDAQ:PROK) - Defense World
PROKIDNEY Earnings Preview: Recent $PROK Insider Trading, Hedge Fund Activity, and More - Nasdaq
ProKidney Corp. (NASDAQ:PROK) Shares Bought by Renaissance Technologies LLC - Defense World
JPMorgan Chase & Co. Buys 19,585 Shares of ProKidney Corp. (NASDAQ:PROK) - Defense World
ProKidney (PROK) Expected to Announce Quarterly Earnings on Friday - Defense World
The ProKidney Corp (PROK) had a good session last reading, didn’t it? - uspostnews.com
ProKidney Corp (PROK) receives a Neutral rating from JP Morgan - knoxdaily.com
ProKidney Corp Inc. (PROK) Price Performance: The Role of Supply and Demand - investchronicle.com
Gaining Ground: ProKidney Corp (PROK) Closes Higher at 1.08, Up 4.85 - DWinneX
Geode Capital Management LLC Grows Stock Position in ProKidney Corp. (NASDAQ:PROK) - Defense World
Is ProKidney Corp (PROK) positioned for future growth? - Sete News
ProKidney Corp (NASDAQ:PROK)’s 12-Month Price Target Currently Stands At 6 - Marketing Sentinel
Major Investment Alert: Carso De-C Inmobiliaria Acquires ProKidney Shares! - TipRanks
ProKidney Corp [PROK] Records 50-Day SMA of $1.0283 - knoxdaily.com
The Psychology of ProKidney Corp Inc. (PROK) Price Performance: Understanding Market Sentiment - investchronicle.com
Analytical Overview: ProKidney Corp (PROK)’s Ratios Tell a Financial Story - DWinneX
Major Investment Alert: ProKidney Stock Sees New Stakeholder! - TipRanks
Major Investment Alert: ProKidney Stock Acquisition! - TipRanks
Major Investment Alert: ProKidney Stock Sees Significant Purchase! - TipRanks
Greensboro’s Once Great Win Is Now A ProKidney Failure - Rhino Times
Major Investment Alert: ProKidney Stock Sees Big Buy-In! - TipRanks
Control empresarial de capitales purchases $628,847 in ProKidney shares - Investing.com
Control empresarial de capitales purchases $628,847 in ProKidney shares By Investing.com - Investing.com Canada
Sei Investments Co. Makes New $69,000 Investment in ProKidney Corp. (NASDAQ:PROK) - Defense World
Critical Review: Candel Therapeutics (NASDAQ:CADL) & ProKidney (NASDAQ:PROK) - Defense World
PROK stock touches 52-week low at $0.49 amid market challenges - Investing.com India
Institutional owners may take dramatic actions as ProKidney Corp.'s (NASDAQ:PROK) recent 32% drop adds to one-year losses - simplywall.st
Bank of New York Mellon Corp Has $388,000 Holdings in ProKidney Corp. (NASDAQ:PROK) - Defense World
Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation - Yahoo Finance
Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK) - Yahoo Finance
PROK stock touches 52-week low at $0.94 amid market challenges - Investing.com India
ProKidney Corp reports results for the quarter ended December 31Earnings Summary - TradingView
ProKidney Hold Rating: Balancing Developmental Progress and Financial Stability Amid Uncertainty - TipRanks
ProKidney Corp (PROK) Reports $163.3 Million Net Loss for 2024, - GuruFocus.com
ProKidney reports larger loss in 2024 as production resumes - Winston-Salem Journal
PROKIDNEY CORP. SEC 10-K Report - TradingView
ProKidney CEO cites 'significant progress' after regenerative medicine company loses $163M in 2024 - The Business Journals
Prokidney Corp Stock (PROK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prokidney Corp Stock (PROK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Control Empresarial de Capital | Add'l Rep. Persons-see Ex.99-1 |
Apr 17 '25 |
Buy |
0.75 |
25,000 |
18,690 |
73,455,330 |
| Control Empresarial de Capital | Add'l Rep. Persons-see Ex.99-1 |
Apr 16 '25 |
Buy |
0.75 |
100,000 |
74,820 |
73,430,330 |
| Control Empresarial de Capital | Add'l Rep. Persons-see Ex.99-1 |
Apr 15 '25 |
Buy |
0.70 |
468,000 |
326,009 |
73,330,330 |
| Control Empresarial de Capital | Add'l Rep. Persons-see Ex.99-1 |
Apr 14 '25 |
Buy |
0.73 |
268,105 |
194,591 |
72,862,330 |
| Control Empresarial de Capital | Add'l Rep. Persons-see Ex.99-1 |
Apr 10 '25 |
Buy |
0.61 |
1,032,218 |
627,692 |
72,592,325 |
| Control Empresarial de Capital | Add'l Rep. Persons-see Ex.99-1 |
Apr 11 '25 |
Buy |
0.61 |
1,900 |
1,155 |
72,594,225 |
| Weber Darin J. | Chief Regulatory Officer |
Sep 19 '24 |
Sale |
2.50 |
16,412 |
41,030 |
103,480 |
1.89%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):